BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Roivant Sciences Stock Surges on Positive Late-Stage Clinical Results
Roivant Sciences Stock Surges on Positive Late-Stage Clinical Results
10
3
BTCCSquare news:
Roivant Sciences (ROIV) shares jumped 11.4% after announcing promising phase 3 trial data for brepocitinib, a potential treatment for dermatomyositis. The drug met all primary and secondary endpoints with a favorable safety profile, positioning it as a potential blockbuster in rare autoimmune diseases.
Priovant Therapeutics, 75%-owned by Roivant, plans to seek FDA approval by mid-2026. With only one currently approved therapy for the 50,000 U.S. patients affected, brepocitinib could capture significant market share as the sole oral treatment in late-stage development.
By:
